The net loss for the fourth quarter of 2025 was $5.2 million, or $0.61 per share, a significant improvement compared to a net loss of $10.9 million, or $2.23 per share, for the same period in 2024. For the full year, the net loss was $13.7 million, or $1.85 per share, down from $15.6 million, or $4.11 per share, in 2024. This reduction in losses indicates improved operational efficiency and cost management.
CEO Chandler Robinson highlighted that 2025 was a productive year for Monopar, marked by multiple data presentations for ALXN1840 and a strengthened balance sheet. The company is preparing for a New Drug Application (NDA) submission for ALXN1840 in mid-2026, which is a critical step towards bringing this innovative treatment to market. Additionally, Monopar has recently enhanced its leadership team with the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, positioning the company for the potential launch of ALXN1840.
The filing also included details about the company's ongoing clinical activities and recent program developments, particularly regarding ALXN1840, which has shown promise in treating Wilson disease, a rare genetic disorder characterized by impaired copper elimination. Monopar's commitment to advancing this treatment is underscored by its recent interactions with the FDA, which have paved the way for the upcoming NDA submission.
Overall, the financial results and strategic updates reflect a positive outlook for Monopar Therapeutics, with expectations of continued progress in its clinical programs and a focus on addressing unmet medical needs in the biopharmaceutical space.
